Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01902-17. Print 2018 Feb.
Previous studies have separately emphasized the importance of host, pathogen, and treatment characteristics in determining short-term or in-hospital mortality rates for patients with methicillin-resistant (MRSA) bloodstream infections. Less is known about the relative importance of these factors and their interactions in determining short-, medium-, and long-term mortality rates. This is an observational cohort study in which data for all patients admitted to the University of New Mexico (UNM) Health Sciences Center (HSC) between July 2002 and August 2013 with MRSA-positive blood cultures were recorded. We collected patients' demographics and treatment data, as well as data on genetic markers of the MRSA isolates. Outcomes of interest were determinants of short-term (within 30 days), medium-term (30 to 90 days), and long-term (>90 days) mortality rates. This study included 273 patients with MRSA bacteremia. Short-, medium-, and long-term mortality rates were 18.7%, 26.4%, and 48%, respectively. Thirty-day mortality rates were influenced by host variables and host-pathogen interaction characteristics. Pitt bacteremia scores, malignancy, and health care exposure contributed to 30- to 90-day mortality rates, while treatment duration of >4 weeks had a protective effect. Age remained a significant risk factor for death at >90 days, while admission leukocytosis was protective. Infection represented the most frequent cause of death for all three time frames; rates varied from 72.6% in the first 30 days and 60% for 30 to 90 days to 35.7% for >90 days ( = 0.003). Host characteristics affect short-, medium-, and long-term mortality rates for MRSA bloodstream infections more than do pathogen genetic markers and treatment factors.
先前的研究分别强调了宿主、病原体和治疗特征在确定耐甲氧西林金黄色葡萄球菌(MRSA)血流感染患者短期或住院死亡率方面的重要性。关于这些因素的相对重要性及其在确定短期、中期和长期死亡率方面的相互作用知之甚少。这是一项观察性队列研究,记录了 2002 年 7 月至 2013 年 8 月期间所有在新墨西哥大学(UNM)健康科学中心(HSC)住院的 MRSA 阳性血培养患者的数据。我们收集了患者的人口统计学和治疗数据,以及 MRSA 分离株的遗传标记数据。感兴趣的结果是确定短期(30 天内)、中期(30 至 90 天)和长期(>90 天)死亡率的决定因素。本研究包括 273 例 MRSA 菌血症患者。短期、中期和长期死亡率分别为 18.7%、26.4%和 48%。30 天死亡率受宿主变量和宿主-病原体相互作用特征的影响。Pitt 菌血症评分、恶性肿瘤和医疗保健暴露导致 30 至 90 天死亡率升高,而>4 周的治疗时间具有保护作用。年龄仍然是>90 天死亡的重要危险因素,而入院白细胞增多是保护性的。感染是所有三个时间段死亡的最常见原因;30 天内的发生率为 72.6%,30 至 90 天为 60%,>90 天为 35.7%(= 0.003)。宿主特征对 MRSA 血流感染的短期、中期和长期死亡率的影响大于病原体遗传标记和治疗因素。